GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (LTS:0A9G) » Definitions » 3-Year FCF Growth Rate

Mereo BioPharma Group (LTS:0A9G) 3-Year FCF Growth Rate : 34.10% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mereo BioPharma Group 3-Year FCF Growth Rate?

Mereo BioPharma Group's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.05.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 34.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 45.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 9 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Mereo BioPharma Group was 67.60% per year. The lowest was 6.20% per year. And the median was 44.70% per year.


Competitive Comparison of Mereo BioPharma Group's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Mereo BioPharma Group's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's 3-Year FCF Growth Rate falls into.



Mereo BioPharma Group 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Mereo BioPharma Group  (LTS:0A9G) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Mereo BioPharma Group 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines